Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Folliculin slows hair growth, and blocking it might help treat hair loss.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.

Plastic surgery has constantly evolved, improving patient care and expanding techniques, especially after the World Wars.

Adding 1% hair fibers to brake materials improves friction and wear, making them more effective.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Foxn1 helps skin cells mature by controlling a specific protein's activity.

Adding human hair fibers and glass micro-spheres to epoxy improves its wear resistance and strength.

MPZL3 is important for controlling the hair growth cycle in mice and humans.

Lrig1 marks a unique group of stem cells in mouse skin that can become different skin cell types.

The gymnast's wrist pain and delayed menstruation are linked to intense exercise, requiring reduced activity and monitoring.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Promising cancer treatments were found, but the manufacturer closed.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

MK-5108 is safe and shows potential against tumors, especially alone.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Baricitinib was effective in treating alopecia areata in two major trials.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.